Provexis plc (AIM:PXS)

Market Cap	13.54M
Revenue (ttm)	1.29M
Net Income (ttm)	-452.72K
Shares Out	2.35B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	203,227
Average Volume	202,927
Open	0.6350
Previous Close	0.6025
Day's Range	0.5710 - 0.6350
52-Week Range	0.0062 - 0.9500
Beta	0.61
RSI	64.97
Earnings Date	Oct 30, 2025

About Provexis

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product. The company sells its products through company’s website a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 2
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PXS

Financial Performance

In 2024, Provexis's revenue was 1.29 million, an increase of 61.13% compared to the previous year's 801,964. Losses were -452,720, -22.78% less than in 2023.